These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 16712986)

  • 41. Changes in out-of-pocket payments for healthcare in Vietnam and its impact on equity in payments, 1992-2002.
    Chaudhuri A; Roy K
    Health Policy; 2008 Oct; 88(1):38-48. PubMed ID: 18423775
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Capping risk adjustment?
    Eugster P; Sennhauser M; Zweifel P
    J Health Econ; 2010 Jul; 29(4):499-507. PubMed ID: 20462647
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Managed competition: the future, not the past.
    Sipkoff M
    Manag Care; 2003 Aug; 12(8):24-7. PubMed ID: 12966847
    [No Abstract]   [Full Text] [Related]  

  • 44. Case-mix adjustment for an expanded renal prospective payment system.
    Hirth RA; Turenne MN; Wheeler JR; Pozniak AS; Tedeschi P; Chuang CC; Pan Q; Slish K; Messana JM
    J Am Soc Nephrol; 2007 Sep; 18(9):2565-74. PubMed ID: 17675667
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Notes from the laboratories of democracy: state government enactments of market- and state-based health insurance reforms in the 1990s.
    Barrilleaux C; Brace P
    J Health Polit Policy Law; 2007 Aug; 32(4):655-83. PubMed ID: 17639016
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Side effects: a dose of competition and access to care.
    Glied S
    J Health Polit Policy Law; 2006 Jun; 31(3):643-56. PubMed ID: 16785302
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Failure to protect: why the individual insurance market is not a viable option for most U.S. families: findings from the Commonwealth Fund Biennial Health Insurance Survey, 2007.
    Doty MM; Collins SR; Nicholson JL; Rustgi SD
    Issue Brief (Commonw Fund); 2009 Jul; 62():1-16. PubMed ID: 19621500
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Universal mandatory health insurance in the Netherlands: a model for the United States?
    van de Ven WP; Schut FT
    Health Aff (Millwood); 2008; 27(3):771-81. PubMed ID: 18474971
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biased selection within the social health insurance market in Colombia.
    Castano R; Zambrano A
    Health Policy; 2006 Dec; 79(2-3):313-24. PubMed ID: 16516333
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The medical expenditure panel survey: a national information resource to support healthcare cost research and inform policy and practice.
    Cohen JW; Cohen SB; Banthin JS
    Med Care; 2009 Jul; 47(7 Suppl 1):S44-50. PubMed ID: 19536015
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Direct versus indirect standardization in risk adjustment.
    Schokkaert E; Van de Voorde C
    J Health Econ; 2009 Mar; 28(2):361-74. PubMed ID: 19111360
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Paying Medicare Advantage plans by competitive bidding: how much competition is there?
    Biles B; Pozen J; Guterman S
    Issue Brief (Commonw Fund); 2009 Aug; 65():1-12. PubMed ID: 19685587
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Does greater Medicare HMO enrollment cause adverse selection into Medigap?
    Desmond KA; Rice T; Fox PD
    Health Econ Policy Law; 2006 Jan; 1(Pt 1):3-21. PubMed ID: 18634700
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The answer is unleashing markets--not government.
    Romney M
    Newsweek; 2009 May 11-18; 153(19-20):39. PubMed ID: 19469334
    [No Abstract]   [Full Text] [Related]  

  • 55. Medicare program; changes to the hospital inpatient prospective payment systems and fiscal year 2007 rates; fiscal year 2007 occupational mix adjustment to wage index; health care infrastructure improvement program; selection criteria of loan program for qualifying hospitals engaged in cancer-related health care and forgiveness of indebtedness; and exclusion of vendor purchases made under the competitive acquisition program (CAP) for outpatient drugs and biologicals under part B for the purpose of calculating the average sales price (ASP). Final rules and interim final rule with comment period.
    Centers for Medicare and Medicaid Services (CMS), HHS
    Fed Regist; 2006 Aug; 71(160):47869-8351. PubMed ID: 16921666
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Progressive or regressive? A second look at the tax exemption for employer-sponsored health insurance premiums.
    Schoen C; Stremikis K; Collins S; Davis K
    Issue Brief (Commonw Fund); 2009 May; 53():1-8. PubMed ID: 19449499
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risky business. Big insurers rig the game to avoid covering people likely to file claims.
    Schmitt CH
    US News World Rep; 2003 Jun; 134(19):42-7. PubMed ID: 12800331
    [No Abstract]   [Full Text] [Related]  

  • 58. Response: The case for risk-based subsidies in public health insurance.
    Van de Ven W
    Health Econ Policy Law; 2006 Apr; 1(Pt 2):195-9; discussion 201-2. PubMed ID: 18634691
    [No Abstract]   [Full Text] [Related]  

  • 59. Managed competition in the Netherlands-a qualitative study.
    Heinemann S; Leiber S; Gress S
    Health Policy; 2013 Feb; 109(2):113-21. PubMed ID: 23031431
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Health insurance and imperfect competition in the health care market.
    Vaithianathan R
    J Health Econ; 2006 Nov; 25(6):1193-202. PubMed ID: 16647770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.